icon-folder.gif   Conference Reports for NATAP  
 
  16th International Workshop
on Clinical Pharmacology of HIV
and Hepatitis Therapy
May 26-28, 2015
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Therapeutic drug monitoring of daclatasvir in HIV/HCV co-infected patients receiving darunavir/ritonavir 800/100mg once-daily
 
 
  Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26-28, 2015, Washington, DC
 
Desnoyer A1, Le MP1, Belissa E1, Pain J-B1, Gervais A2, Chas J3, Valantin MA4, Perré Ph5, Salmon-Céron D6, Dominguez S7, Larrouy L8, Yazdanpanah Y2, Peytavin G1,8
1APHP, Bichat-Claude Bernard Hospital, Clinical Pharmaco-Toxicology Department, 2APHP, Bichat-Claude Bernard Hospital, Infectious Diseases & Tropical Department, Paris, France, 3APHP, Tenon Hospital, Infectious Diseases & Tropical Department, Paris, France, 4APHP, Pitié-Salpétrière Hospital, Infectious Diseases & Tropical Department, APHP, Paris, France, 5CHD Vendée, Internal Medicine Department, La Roche sur Yon, France, 6APHP, Cochin Hospital, Internal Medicine Department, Paris, France, 7APHP, Henri Mondor Hospital, Clinical Immunology Department, Créteil, France, 8APHP, Bichat-Claude Bernard Hospital, Virology Department, Paris, France, 9IAME, UMR 1137, INSERM, Paris, France Corresponding author: Dr Desnoyer A, audedesnoyer@gmail.com, Laboratoire de Pharmaco-Toxicologie, APHP, Groupe Hospitalier Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, Tel: +33 1 40 25 84 54

Pharm1.gif

Pharm2.gif

Pharm3.gif

Pharm4.gif

Pharm5.gif

Pharm6.gif

Pharm7.gif

Pharm8.gif